

Erratum: Conditional Euribor bull flatteners

Already full up on steepeners? Try some front-end bull flatteners for a change

Positioning in Europe is at an extreme owing to the significant carry found in steepening trades. But at the same time, slopes are similarly at an extreme with 2s30s at levels not seen since 2003. In this risky mix, we recommend front-end Euribor bull flatteners (Mar expiry), which can be entered into at decent levels with positive carry. Although there are other OTC flatteners with positive carry (e.g., small amounts in short-dated 2s5s bull flatteners and 5s10s bear flatteners), there are few that have such decent carry over short horizons, meanwhile benefiting from adjustments to further ECB accommodation.

***The risks were incorrectly reported for a 1000 lot trade in the original document. They have been corrected in this document.**

Trade Idea: Sell 5000 lots ERH5C 99.875 / Buy 5000 lots 2RH5C 99.375 for 15.5 ticks (EUR1.937mn, ref ERH5 at 99.44). Expected 3m Carry of 1.79 ticks EUR224k, expected carry to term of 13.8 ticks.

Trade: Front-end flatteners

Since the ECB's action the curve has moved increasingly to incorporate further accommodation. Nonetheless, the significant appeal of long-end steepeners has meant that many clients hold many steepeners. Meanwhile, the curve slope is nearing all-time steep levels with 10s30s and 5s30s both close to early 2004 levels (where it was only steeper in mid-2003 and early-1999). Although there are flatteners to help offset this risk, few offer the decent pickup of this trade.

Fig. 1: Package price of 15.5 ticks, with carry of 1.79 ticks over 3m

Decent carry even if flattening does not happen

Recent carry Green flattening does not happen.

EUR Mid-Curve Bull Flattener: Mar-15 Expiry, White-Green		
BBG Code	ERH5C 99.875	2RH5C 99.375
Underlying Futures	Mar 2015	Mar 2017
Position	Short	Long
Implied Rate %	0.178	0.578
Futures Price	99.823	99.423
Strike	99.875	99.375
Option Price (ticks)	2.50	18.00
Package Price (ticks)	15.50	

Aged 3-month		
Aged Price (ticks)	1.53	18.82
Carry (ticks)	-0.97	0.82
Package Carry (ticks)	1.79	
Package Carry (%)	11.6%	

Source: Nomura Research

Figure 1 shows that the short leg contributes little to the actual cost of the trade, and it is a major source of the carry (since the Whites mostly carry negatively). All the carry

Global Markets Research

19 June 2014

Research analysts

Quantitative Strategies

Nick Firoozye - Nlplc
nick.firoozye@nomura.com
+44 20 7102 1660


Qilong Zhang - NIHK
qilong.zhang@nomura.com
+852 2252 6191

figures presented are for a 3m horizon (where the underlying futures roll into Dec contracts). We note that there are approximately 4.4 ticks more carry over the following 3m horizon, and 7.6 ticks over the 3m until expiry or a total of 13.8 ticks to expiry.

Although the ECB's delivery of nearly as much policy action as the market had expected resulted in an immediate post-meeting flattening, recent trends have reversed this and entry levels on the trade (3rd-11th contract, corresponding to 33m3m-9m3m FRA spread) are close to mid-May levels (see Figure 2).

Fig. 2: 3rd-11th Contract and 2s5s slope. Post ECB flattening has been largely retraced

Entry levels close to mid-May



Source: Nomura Research

The current futures (ERH5-ERH7) spread is 40bp, while it ages into the spot (ERZ4-ERZ6) spread of 11.7bp. Meanwhile, the strike spread of 50bp gives considerable leeway for selloffs, as we see in Figure 3.

Fig. 3: Enter into the flattener at steep strikes

Carry is largely from curve positioning

	Short ERH5C	Long 2RH5C	Spread
	99.875	99.375	(bp)
Spot	21.7	33.4	11.7
Forward	17.8	57.8	40.0
Strike	12.5	62.5	50.0

Source: Nomura Research

The spread itself is highly correlated with the 2s5s slope as we see in Figure 4 with a correlation of 98% in levels, or a 91% correlation with 2s10s. The sparkline plots on the left clearly show a similar time-series profile of the spread to these two slopes, with slightly less correspondence with 5s10s. And, unlike the Whites-Reds slopes, this Whites-Greens has little similarity with the 2-5-10 fly, which has come under considerable receiving pressure lately.

Fig. 4: 3rd-11th Contract spread is most highly correlated with 2s10s and 2s5s

10y History	Spread	Current	High	Low	Mean	Volatility	Z-Score	Correlation to Spread
	9m3m	0.28	5.46	0.26	2.21	138.6	-1.39	
	33m3m	0.72	5.02	0.65	2.83	116.0	-1.82	
	33m3m-9m3m	43.5	187.6	-78.2	62.8	52.0	-0.37	
	2s5s	40.6	116.3	-44.1	46.4	32.3	-0.18	0.98
	2s10s	124.9	203.4	-59.4	101.1	57.8	0.41	0.91
	5s10s	84.3	98.1	-21.5	54.7	27.7	1.07	0.76
	10s30s	74.5	77.2	-56.7	34.6	21.5	1.86	0.36
	2s30s	199.4	238.6	-74.2	135.6	72.1	0.88	0.84
	2s5s10s	-43.7	33.7	-49.5	-8.3	16.9	-2.10	0.62


Source: Nomura Research

Figure 5 shows that although both vols have been falling lately, the fall has been far more precipitous in the midcurves. Consequently, the spread between the two is close to

all-time lows, at a percentile of just under 10%. This should indicate that entry levels are relatively attractive.

Fig. 5: ERH5 vols and 2RH5 vols

Vol spreads are near their all-time lows (cheapest)



Source: Quikstrike.com, Nomura Research

In terms of risks for the trade, as we see in Figure 6, the trade is modestly short parallel shifts in the curve (which we believe unlikely to happen in this dovish regime), is short theta, short gamma and long vega. All risks are to a full-rate model (which is not calibrated to the Dec-17 future). Many futures traders may prefer the simpler Bachelier (Normal) model, where overall trade delta and gamma would depend on correlations.

Fig. 6: Trade Risks

Modestly long vega and short gamma

EUR Mid-Curve Bull Flattener: Mar-15 Expiry, White-Green (5000 Contracts)										
Contract Name	Contracts	Futures Price	Strike	Price (ticks)	Premium €	Delta €/bp	Vega €/bp	Theta €/day	Gamma €/bp2	
ERH5C 99.875	-5000	99.823	99.875	2.50	-312,500	52,180	-37,353	1,305	-5,531	
2RH5C 99.375	5000	99.423	99.375	18.00	2,250,000	-81,763	43,311	-4,111	1,763	
					1,937,500	-29,584	5,958	-2,806	-3,768	

Source: Nomura Research

Because of the recent positive correlation between rates and vol, the mark-to-market from any bearish surprises should be buffered by the positive vega, but of course holding the contract until term is likely to result in further gains, because of the large positive carry.

Trade Idea: Sell 5000 lots ERH5C 99.875 / Buy 5000 lots 2RH5C 99.375 for 15.5 ticks (EUR 1.937mn, ref ERH5 at 99.44). Expected 3m carry of 1.79 ticks EUR 224k, expected carry to term of 13.8 ticks.

Appendix A-1

Analyst Certification

I, Nick Firoozye, hereby certify (1) that the views expressed in this Research report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of my compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of my compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.

Important Disclosures

Online availability of research and conflict-of-interest disclosures

Nomura research is available on www.nomuranow.com/research, Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne. Important disclosures may be read at <http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx> or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email grpsupport@nomura.com for help.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Nomura Global Financial Products Inc. ("NGFP") Nomura Derivative Products Inc. ("NDPI") and Nomura International plc. ("Nlplc") are registered with the Commodities Futures Trading Commission and the National Futures Association (NFA) as swap dealers. NGFP, NDPI, and Nlplc are generally engaged in the trading of swaps and other derivative products, any of which may be the subject of this report.

ADDITIONAL DISCLOSURES REQUIRED IN THE U.S.

Principal Trading: Nomura Securities International, Inc and its affiliates will usually trade as principal in the fixed income securities (or in related derivatives) that are the subject of this research report. Analyst Interactions with other Nomura Securities International, Inc. Personnel: The fixed income research analysts of Nomura Securities International, Inc and its affiliates regularly interact with sales and trading desk personnel in connection with obtaining liquidity and pricing information for their respective coverage universe.

Valuation methodology - Fixed Income

Nomura's Fixed Income Strategists express views on the price of securities and financial markets by providing trade recommendations. These can be relative value recommendations, directional trade recommendations, asset allocation recommendations, or a mixture of all three. The analysis which is embedded in a trade recommendation would include, but not be limited to:

- Fundamental analysis regarding whether a security's price deviates from its underlying macro- or micro-economic fundamentals.
- Quantitative analysis of price variations.
- Technical factors such as regulatory changes, changes to risk appetite in the market, unexpected rating actions, primary market activity and supply/ demand considerations.

The timeframe for a trade recommendation is variable. Tactical ideas have a short timeframe, typically less than three months. Strategic trade ideas have a longer timeframe of typically more than three months.

Disclaimers

This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. The term "Nomura Group" used herein refers to Nomura Holdings, Inc. or any of its affiliates or subsidiaries and may refer to one or more Nomura Group companies including: Nomura Securities Co., Ltd. ('NSC') Tokyo, Japan; Nomura International plc ('Nlplc'), UK; Nomura Securities International, Inc. ('NSI'), New York, US; Nomura International (Hong Kong) Ltd. ('NIHK'), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. ('NFIK'), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at <http://dis.kofia.or.kr>); Nomura Singapore Ltd. ('NSL'), Singapore (Registration number 197201440E, regulated by the Monetary Authority of Singapore); Nomura Australia Ltd. ('NAL'), Australia (ABN 48 003 032 513), regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number 246412; P.T. Nomura Indonesia ('PTNI'), Indonesia; Nomura Securities Malaysia Sdn. Bhd. ('NSM'), Malaysia; NIHK, Taipei Branch ('NITB'), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited ('NFASL'), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400 018, India; Tel: +91 22 4037 4037, Fax: +91 22 4037 4111; CIN No : U74140MH2007PTC169116, SEBI Registration No: BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034, MCX: INE261299034) and Nlplc, Madrid Branch ('Nlplc, Madrid'). 'CNS Thailand' next to an analyst's name on the front page of a research report indicates that the analyst is employed by Capital Nomura Securities Public Company Limited ('CNS') to provide research assistance services to NSL under a Research Assistance Agreement. CNS is not a Nomura entity.

THIS MATERIAL IS: (I) FOR YOUR PRIVATE INFORMATION, AND WE ARE NOT SOLICITING ANY ACTION BASED UPON IT; (II) NOT TO BE CONSTRUED AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE ILLEGAL; AND (III) BASED UPON INFORMATION FROM SOURCES THAT WE CONSIDER RELIABLE, BUT HAS NOT BEEN INDEPENDENTLY VERIFIED BY NOMURA GROUP.

Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information.

Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document.

Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice.

Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Any MSCI sourced information in this document is the exclusive property of MSCI Inc. ('MSCI'). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates.

Russell/Nomura Japan Equity Indexes are protected by certain intellectual property rights of Nomura Securities Co., Ltd. and Russell Investments. Nomura Securities Co., Ltd. and Russell Investments do not guarantee the accuracy, completeness, reliability, or usefulness thereof and do not account for business activities and services that any index user and its affiliates undertake with the use of the Indexes. Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements. Clients outside of the US may access the Nomura Research Trading Ideas platform (Retina) at <http://go.nomuranow.com/equities/tradingideas/retina/>.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns.

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment.

The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction.

This document has been approved for distribution in the UK and European Economic Area as investment research by Nlplc. Nlplc is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Nlplc is a member of the London Stock Exchange. This document does not constitute a personal recommendation within the meaning of applicable regulations in the UK, or take into account the particular investment objectives, financial situations, or needs of individual investors. This document is intended only for investors who are 'eligible counterparties' or 'professional clients' for the purposes of applicable regulations in the UK, and may not, therefore, be redistributed to persons who are 'retail clients' for such purposes. This document has been approved by NIHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NIHK. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document. Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of 1934. The entity that prepared this document permits its separately operated affiliates within the Nomura Group to make copies of such documents available to their clients.

This document has not been approved for distribution to persons other than 'Authorised Persons', 'Exempt Persons' or 'Institutions' (as defined by the Capital Markets Authority) in the Kingdom of Saudi Arabia ('Saudi Arabia') or 'professional clients' (as defined by the Dubai Financial Services Authority) in the United Arab Emirates ('UAE') or a 'Market Counterparty' or 'Business Customers' (as defined by the Qatar Financial Centre Regulatory Authority) in the State of Qatar ('Qatar') by Nomura Saudi Arabia, Nlplc or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or in Qatar or to any person other than 'Authorised Persons', 'Exempt Persons' or 'Institutions' located in Saudi Arabia or 'professional clients' in the UAE or a 'Market Counterparty' or 'Business Customers' in Qatar. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are an 'Authorised Person', an 'Exempt Person' or an 'Institution' in Saudi Arabia or that you are a 'professional client' in the UAE or a 'Market Counterparty' or 'Business Customers' in Qatar and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the UAE or Saudi Arabia or Qatar.

NO PART OF THIS MATERIAL MAY BE (I) COPIED, PHOTOCOPIED, OR DUPLICATED IN ANY FORM, BY ANY MEANS; OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors

or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training.

Additional information is available upon request and disclosure information is available at the Nomura Disclosure web page:

<http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx>

Copyright © 2014 Nomura International plc. All rights reserved.